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Despite the promising anti-oxidant and anti-inﬂammatory effects of resveratrol (RES) on human health, pre-clinical and
clinical studies are frequently disappointing, probably due to its low water-solubility and poor bioavailability. Even
though a hormeticmode of action was clearly established for RES, the high doses commonly used tomitigate these issues,
lead to adverse effects. Common hallmarks of multiple pathologies results from pathological-enhanced endothelial
permeability due to both enhanced inﬂammation and matrix metalloprotease-9 (aMMP-9) activities. The main aim of
this work was to optimize the RES capacity to inhibit aMMP-9 by using a new class of solvents, natural deep eutectic
solvents (NADES) for a newRES formulation as compared with dimethyl-sulfoxide (DMSO). To obtain the appropriate
NADES, 18 compounds combinations were prepared to select those exhibiting the optimized capacity to dissolve RES.
The RES-NADES 1,2-propanediol:choline-chloride:water (PCW, 1:1:1 molar ratio) and compared with RES-DMSO
for their aMMP-9-inhibitory capacities. Low concentrations of RES-NADES/PCW formulation exhibited both a
biocompatible solubility and a strong increased aMMP-9-inhibitory activity, at least 10-fold, higher than RES-DMSO,
reaching its hormetic mode of action. Following in vivo validations, some particular NADES could potentially be
considered as the new generation of formulation for druggable compounds.
Practical applications: Formulation of resveratrol inNatural Deep Eutectic solvents (NADES) optimizes its capacity to
inhibit active matrix metalloprotease-9. The Resveratrol-NADES 1,2-propanediol:choline-was the most efﬁcient and low
concentrations exhibited both a biocompatible solubility and an increased aMMP-9-inhibitory activity, at least 10-fold,
higher than RES-DMSO. Consequently, the NADES/PCW formulation allowed resveratrol to reach its hormetic mode of
action. Following in vivo validations, some particular NADES could potentially be considered as the new generation of
formulation for druggable compounds.
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1 Introduction
Numerous clinical studies have been performed with
resveratrol (3,40,5-trihydroxystilbene, RES), a plant poly-
phenol from the stilbenoid series (Fig. 1), to assess its
capacity to promote beneﬁcial effects on human health
[1, 2]. IndeedRES, is considered as a dietary anti-oxidant [3],
able to decrease inﬂammatory processes, including the
inhibition of the gelatinolytic metalloproteases (gMMP)-2
and 9 activities [4]. The activity increase of gMMP is
strongly related to pathological enhancement of endothelial
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permeability is a common characteristic of several infectious
and systemic diseases, including HIV-1 [5], dengue virus
infection [6], Hantavirus cardiopulmonary syndrome [7],
and cancer [8]. There are multiple MMP-9 upstream
enhancers, such as pro-inﬂammatory cytokines (tumor
necrosis factor-a, TNF-a), growth and transcriptional
factors [9]. Despite the previous mentioned positive effects
of RES in human health, its low-water solubility, mode of
action, targets, route and dose of administration, as well as its
low bioavailability, preclude its regular use as a therapeutic
approach [10–13]. In order to overcome the poor water-
solubility of RES, and to be able to observe measurable
effects, some groups, using elevated RES doses (1000 to
1500mg/person/day), did not get the positive effects
observed in humans at low concentrations (150mg/day) as
reported by others [14, 15] but, rather observed adverse
effects [16, 17]. For more than10 years, such a phenomenon
has been assigned to hormetic effect of RES [18–23]. Some
synonymous terms of hormesis have also been used, such as
biphasic dose-response effect, adaptive response, or pre-
conditioning effects [18, 24]. All these data advocate for the
use of the lowest effective RES doses, in preclinical and/or
clinical studies. Different formulations have been set up to
reach the goal to solve both the RES solubility and
bioavailability issues: Micellar solutions with bile acids [25],
carboxymethyl chitosan (CMCS) and RES-loaded CMCS
nanoparticles (RES-CMCSNPs) [26], N-trimethyl chitosan
(TMC) grafted by palmitic acid (TMC-g-PA) [27], cyclo-
dextrin, and co-encapsulation of cyclodextrin inclusions in
liposomes [28]. Some of these nanotechnology-based
formulations were able to successfully “enhance the RES
clinical potential” [29].
For the ﬁrst time in this ﬁeld, this study is using a new class
of solvents so called Natural Deep Eutectic Solvents
(NADES), recently discovered by Choi et al. [30], to prepare
new formulations of RES. NADES consist in a mixture, in
speciﬁc molar ratios, of two or more plant-based metabolites,
exhibiting strong capacity of self-association through non-
covalent interactions, ionic interactions, hydrogen bonding,
and van der Waals forces (lipophilic–lipophilic and p–p
interactions), leading to a supramolecular assembly. The
molecules formingsuchstructuresstayconnectedtoeachother
throughawell-organized three-dimensional system, acting as a
new entity with properties mostly different from those of pure
isolatedcomponents (meltingpoint, solvingpower,. . .).Oneof
the most important changes is the drastic lowering of melting
point:NADESact like a pure compound (eutectic) andmelt at
very low temperature (deep). Unlike the very similar non-
covalentderivatives suchas ionic liquids (IL)anddeepeutectic
solvents (DES), the main components of NADES are all
natural: Sugars, amino acids, and organic acids. NADES are
very “good solvents” due to the strong intermolecular
interactions between NADES components, They are used
in broad-spectrum applications, including cosmetics, media
for enzymatic reactions [31, 32], enhancers for extraction of
bioactive natural products, and nucleic acids [33, 34]. In
addition, NADES have been shown to be good solvents for
non-water-soluble small molecules (polyphenols), or even,
macromolecules, (starch, cellulose, nucleic acids [33]).
From 18 compound combinations were used to prepare
different NADES, we selected those exhibiting the highest
RES solubilizing power and were used to formulate RES
(RES-NADES). The best combination used as a RES
formulation was compared with a RES DMSO-formulation
(RES-DMSO), which is the most current solvent of medium
polar substrates for in vitro studies. For the ﬁrst time here, we
show that RES was not only easily dissolved in a particular
NADES, but also that this formulation exhibited at least a
10-fold higher aMMP-9 inhibitory effect as compared with
the RES-DMSO formulation, making possible to lower RES
doses and thus able to reach the hormetic effects conditions.
2 Materials and methods
2.1 Chemicals and reagents
Dimethyl sulfoxide (DMSO) andMTT (3-[4,5-Dimethylth-
iazol-2-yl]-2,5-diphenyltetrazolium bromide; Thiazolyl
blue), as well as individual NADES components were
purchased from Sigma–AldrichTM (Marnes-la-Coquette,
France), Choline chloride (ChCl) was dried under vacuum
at 608C over a silica gel for 72 h before use. TNF-a was
purchased from PeproTechTM (Paris, France), and all other
chemicals used in this study were highly puriﬁed molecular
grade reagents (Sigma, Paris, France). RESwas isolated from
stalks of Vitis vinifera, Vitaceae, and highly-puriﬁed (98%)
according to the process described by Delaunay et al. [35].
2.2 Preparation of natural deep eutectic solvents
A set of 18 natural deep eutectic solvents were prepared
according to theproceduremodiﬁed fromAbbott [36].Brieﬂy,
theseNADESwere prepared as follows:Components 1, 2 and
3, from(Table1),weredirectlyweighed inaﬂask, avoidingany
contactwith theairmoisture, toget amolar ratioasdescribed in
(Table 1). Finally, all mixtures to form a potential NADES
were heated and stirred with an orbital shaker at 250 rpm and
incubated at 608C until a clear solution was formed. Among
these solvents, three solvents were able to solubilize RES (as
visually assessed), NADES composed of: 1,2-propanediol:
choline-chloride:water (1:1:1) (NADES/PCW), Glucose:
Figure 1. Resveratrol structure and numbering of trans-
resveratrol.
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ChCl:Water (1:2.5:2.5) (NADES/GCW), and Malic acid:
ChCl (1:1) (NADES/MA). NADES/PCW was further
selected based upon both its higher RES solubilizing capacity
as well as its individual low cytotoxicity.
2.3 Determination of resveratrol solubility in
NADES/PCW and DMSO
To assess the RES concentration by UPLC-UV analysis
(Accela-Thermo scientiﬁc), a calibration curve was realized
using standard samples of RES, diluted in water to
respectively get ﬁnal concentrations of 16, 8, 4, 2, and
1mg/mL. The UPLC-UV analysis of RES was performed
using an Xbridge BEH C18 2.5mm column (2.1 100mm)
and an Xbridge BEHC18 2.5mm pre-column (2.1 5mm).
Solvents A (H2O) and B (CH3CN) were used according to
the timetable in the following gradient: 80/20 from 0 to
3min, 80/20 to 50/50 from 3 to 10min, 50/50 to 80/20 from
10 to 11min, all of them at a ﬂow rate of 0.3mL/min. The
RES detection was performed at 310nm. In order to
determine the experimental working solubility of RES in
both solvents NADES and DMSO, 20mg of RES powder
were dissolved in either 1mL of NADES/PCW or 1mL of
DMSO and heated overnight at 408C. Subsequently, these
preparations were centrifuged for 5min at 1500 rpm and
supernatants were recovered. To prepare a theoretical RES
concentration of 1mg/mL, 10mL of the respective recovered
supernatant were diluted with 190mL of methanol, from
which a theoretical 10mg/mL solution was realized in
H2O (10mL in 990mL H2O). All these solutions were
analyzed by the UPLC-UV method (using the calibration
curve) allowed us to determine the actual concentration
in each sample and to compare the corresponding RES
solubility in bothNADES/PCW andDMSO (supplementary
Fig. S1).
2.4 Cell culture
A TNF-a activated human leukemia cell line (THP-1) was
used as a source of active MMP-9 production. In the aim to
assess the MMP-9-inhibitory activity of RES, RES was
dissolved in two kinds of solvents, NADES/PCW and
DMSO. The cytotoxic activity of different compounds was
assessed using the MTT assay on different cell types,
including primary human umbilical vein endothelial cells
(HUVEC), human leukemia cell line (THP-1), the human
brain micro-vascular endothelial cell line (hcMEC/D3) was
derived from primary human temporal lobe micro-vessels
(immortalized with a lentiviral vector transduction with the
catalytic subunit of human telomerase (hTERT) and SV40
large T antigen [37] as well as other cell lines including the
human pancreatic adenocarcinoma BxPC3, and the human
breast adenocarcinoma MDA MB-231. Both THP-1 and
BxPC3 were cultured in RPMI 1640, whereas MDA
MB-231 was cultured in DMEM medium, and both media
were supplemented with 10% heat-inactivated FBS, penicil-
lin G 100U/mL and streptomycin 100mg/mL purchased
from Fisher ScientiﬁcTM (Illkirch-Graffenstaden, France).
HUVEC were maintained in EndoGroTM low-serum culture
media kit purchased fromMerckMilliporeTM (Paris, France)
and hcMEC/D3were maintained in EBM-2mLVTM culture
media kit purchased from Lonza (Basel, Switzerland).
2.5 Inhibition of the MMP-9 gelatinolytic activity
In the presence of TNF-a 10ng/mL, THP-1monocytes were
seeded at 3 105 cell/mL in 24-well plate andwere incubated
with different concentrations of RES (1, 2, 4, 8, 10, 20,
and 30mM) dissolved either in DMSO or NADES/PCW.
Different THP-1 controls were prepared by incubating cells
with each solvent in RPMI cell culture medium at a ﬁnal
concentration of 0.2% DMSO or 0.2% NADES/PCW, in
the presence or in the absence of TNF-a. After 24 h of
cell culture in these conditions, 1mL of supernatants were
collected and centrifuged at 1 200 rpm at 258C for 5min
before their storage at 808C up to the zymogram analysis.
2.6 Zymography
The gelatinolytic activity of MMP-9 was assessed using a
zymography approach as described by Pan et al. [38]. Brieﬂy,
supernatantswere collected asmentionedaboveand thawed to
beelectrophoretically separated ina10%SDS-polyacrylamide
gel electrophoresis (PAGE) containing 1% gelatin in the
absenceof reducingagents.After theelectrophoresis, gelswere
washed three times in a solution of 2.5% Triton X-100,
followed by incubation with a gelatinase buffer (NaCl
Table 1. Components of tested natural deep eutectic solvents
NADES Compound 1
Compound
2
Compound
3
Molar
ratio
1 Glycerol ChCl - 2:1
2 Lactic acid Betaine - 2:1
3 Lactic acid ChCl - 10:1
4 Malic acid ChCl - 1:1
5 Malic acid Glycine - 1:1
6 Malic acid Proline - 1:3
7 Malonic acid ChCl - 1:1
8 Urea ChCl - 2:1
9 1,2-propanediol ChCl Water 1:1:1
10 Glucose ChCl Water 1:2.5:2.5
11 Glycerol ChCl Water 2:1:2
12 Glycerol Proline Sucrose 9:4:1
13 Lactic acid Glucose Water 5:1:1
14 Lactic acid Proline Water 1:1:0.25
15 Malic acid Proline Water 1:1:3
16 Sucrose ChCl water 1:1:1
17 Sucrose ChCl Water 1:4:4
18 Urea ChCl Water 2:1:2
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200mM, Tris Base 50mM, CaCl2 5mM, and ZnCl2
0.25mM; pH 7.5) on an orbital shaker at 100 rpm at
378C for 24h. Then, gels were stained using the Coomassie
Blue-staining solution (0.025%Coomassie Blue, 40%metha-
nol, and 10% acetic acid) for 1 h, followed by treatment of
distaining solution (glacial acetic acid 10% and methanol
20%), until white bands are formed surrounded by the blue
background.Gelbandswerephotographedandanalyzedusing
GelAnalyzer 2010aTM software.
2.7 MTT cytotoxicity assay
The MTT cytotoxicity assay relies on the reading intensity of
the converted formazan blue crystals from tetrazolium dye by
living cell, the followed protocol was modiﬁed of the protocol
recommendedbyMosmann[39].THP-1,BxPC3,MDA-MB
231, and hcMEC/D3 cells were seeded at 5 103 cells/well in
96-well plate for 24h. While HUVEC were seeded at 1104
cells/well density in the same conditions. Then, supernatants
were discarded and plates were either treated with different
concentrations of NADES/PCW, NADES/GCW, NADES/
MAorDMSO(0.5,1, and2%),orwithserialdilutions (10,20,
40, and 80mM) of each RES formulation (RES in NADES/
PCW or RES in DMSO). Samples were assayed in duplicates
for each concentration, and normalized against negative
control of each solvent diluted in the corresponding cell
culture medium ie., 0.2% NADES (PCW, GCW, MA)-
treated or 0.2% DMSO-treated. Subsequently, plates were
incubated for additional 72h in a CO2 humid chamber at
378C before replacing the medium by MTT in a serum-free
medium and incubated for four additional hours. To dissolve
formazan crystals, SDS–HCl10%was added to eachplate and
incubated at 378C for 2h, the optical density was measured at
570nm (against the reference, 690nm) using a TECANTM
plate reader (Paris, France).
2.8 Statistic analyses
Experimental data from each group were analyzed using
GraphPad PrismTM v.5 software. To analyze the differences
between NADES/PCW and DMSO treated groups, one-
paired Student t-test was carried out. All experiments were
done least three times with replicates equal or higher than
two. The same test was also applied for the cytotoxicity assay
between different groups. Values of p 0.05 were considered
statistically signiﬁcant.
3 Results
3.1 Toxicity assay of NADES (PCW, GCW, and MA)
and DMSO
Some particular NADES including PCW, GCW, and MA,
preselected for their capacity to solubilize RES (by
visualization), were assessed for their cytotoxic effects on
either THP-1 (Fig. 2A) monocytes or primary HUVEC
(Fig. 2B), using theMTT assay. The results showed that at a
2% NADES/PCW concentration exhibited high deleterious
impact on respective THP-1 and HUVEC viability of 71 and
85%, respectively. DMSO decreased the viability of THP-1
and HUVEC to 60 and 80%, respectively. When NADES/
PCW or DMSO was assayed at the lower concentration of
0.5%, no toxicity was observed neither against THP-1, nor
HUVEC. NADES/GCW exhibited high cell toxicity at 2%
that rapidly declined in function of a decreased concentra-
tion. In contrast, NADES/MA was extremely toxic at all the
tested concentrations for both THP-1 and HUVEC. Since,
NADES/PCW and DMSO exhibited the best solubility
(supplementary material, Fig. S1) and the lowest cytotoxicity
of NADES/PCW (Fig. 2C) and DMSO (Fig. 2D) was
extended to other cell types, including BxPC3, hcMec/D3
and MDA MB-231. The highest cytotoxicity effect of
NADES/PCW and DMSO was observed at 2% that
remained relatively moderated, since the cell observed
viability varied from 60 to 81% in these cells (Table 2). In
contrast, the cytotoxicity was drastically reduced at the
lowest assayed concentration of 0.5%.
3.2 Resveratrol cytotoxicity
To properly assess the cytotoxicity of RES, the ﬁnal used
concentration of solvents, either NADES/PCW or DMSO to
prepare RES was 0.2%, at least ﬁvefold reduced concentra-
tion as compared with their cytotoxic effect at a concentra-
tion of 1% (Fig. 2). These results show that high
concentrations (40 and 80mM) of RES have a similar high
cytotoxicity level for both THP-1 monocytes (Fig. 3A) and
primary HUVEC (Fig. 3B). In addition, as shown in Table 3,
the 50% of lethal concentration (LC50) of both RES
formulations for THP-1 and HUVEC were relatively high,
as established using GraphPadTM from Prism v.5 software.
Indeed, both LC50 values of RES-NADES/PCW and RES-
DMSO tested with THP-1 monocytes were close to 40mM.
While the LC50 of RES-NADES/PCW and RES-DMSO
tested with primary HUVEC were similar, respectively 60
and 64mM. In contrast, for the lower concentrations
NADES/PCW and DMSO allowed high cell viability as
compared to the negative control cells submitted to RES
vehicles.
3.3 Resveratrol formulated with NADES/PCW or
DMSO and the MMP-9 activity
The MMP-9-inhibitory activity of RES dissolved in 0.2%
NADES/PCW or 0.2% DMSO was assessed on a culture of
TNF-a-activated THP-1 monocytes, which shed large
amounts of activeMMP-9 into the supernatant. Zymography
results (Fig. 4A) clearly showed a MMP-9-inhibitory activity
of RES. The pixel density analyses of each gel band
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representing theMMP-9 activity conﬁrmed a decrease of this
activity in function of the inhibitory activity of RES. These
data were plotted for each concentration of both RES
formulations (Fig. 4B). We must stress that a signiﬁcant
increase of the RES-NADES/PCW-MMP-9 inhibitory
activity was observed at low RES concentrations up to
1mM that was more than 10-fold stronger than the limited
inhibitory activity of RES-DMSO. Thus, evidencing that the
NADES/PCW vehicle was able to conﬁrm and enhance the
hormetic mode of action of RES as compared with its limited
dose-response activity when dissolved in DMSO.
4 Discussion
Our ﬁndings revealed that the selected natural deep eutectic
solvent 1,2-Propanediol 1,2: ChCl:water or NADES/PCW
(1:1:1) was able to dissolve stalks-extracted RES native
pure powder. The UPLC-UV quantiﬁcation analyses have
evidenced that RESwas completely soluble inNADES/PCW
at a RES-saturated concentration of 20 g/L at 408C, and
that this solubility was similar than the one measured in
the RES-DMSO formulation (supporting information ﬁle,
Fig. S1). Since the NADES/PCW has exhibited both the
highest visual solubilizing power and lower cytotoxicity of
RES as compared with the two other selected RES solvents
NADES/GCW and NADES/MA (Fig. 2), these latter were
discarded and only NADES/PCW was used to assess the
capacity of RES to inhibit the active form of MMP-9
produced from TNF-a-activated THP-1 monocytes. The
individual toxicity of NADES/PCW, DMSO, or resveratrol
was assessed using the MTT assay. Thus, we observed that
both NADES/PCW and DMSO, in the absence of RES were
both toxic at the concentration of 2%, as shown in (Table 2).
Figure 2. In vitro cytotoxic effects of different RES solvents: NADES (PCW, GCW, and MA) and DMSO. Increasing concentrations 0.5, 1,
and 2% of NADES/PCW, NADES/GCW, NADES/MA, or DMSO were incubated with either THP-1 monocytes (A) or primary HUVEC (B)
and then submitted to MTT cytotoxicity assay. Subsequently, in the same conditions these data were extended to other three different cell
types including BxPC3, hcMec/D3, andMDAMB-231 for solvent having previously shown the lowest cytotoxic effects NADES/PCW (C) and
DMSO (D). Values are mean of three experiments standard deviation. p0.05, and p0.001.
Table 2. Cell viability assay of either NADES/PCW or DMSO in the absence of RES
Cells viability (%)
Solvent 2% HUVEC THP-1 hcMec/D3 BxPC3 MDA MB-231
NADES/PCW 85 71 81 69 60
DMSO 80 60 63 75 73
1700171 (5 of 9) A. Shamseddin et al. Eur. J. Lipid Sci. Technol. 2017, 119, 1700171
 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.ejlst.com
In contrast, at a ﬁnal concentration of 0.5% of either
NADES/PCW or DMSO vehicle alone allowed a high
viability rate, close to 100%, of tested cells. In contrast, RES-
NADES/PCW and RES-DMSO formulations exhibited
similar toxic effects when used at 40 and 80mM on THP-
1 monocytes and HUVEC. Moreover, lethal concentrations
able to kill 50% (LD50) of cultivated primary HUVEC were
respectively reached at 60 and 64mMof RES-NADES/PCW
and RES-DMSO respectively as compared with LD50 on
THP-1 monocytes, which both were reached around 40mM.
These latter values showed that these formulations were less
toxic for primary endothelial cells, which are the main
physiological targets of the active MMP-9. In addition,
independently of the RES formulation, below these concen-
trations, no toxic effects of RES were observed. These
observations are extremely encouraging for the future in vivo
experiments.
Since this RES-NADES/PCW was diluted in different
cell culture media to proceed to test the biological activity of
RES proposed in this work, we have observed that RES
dissolved in the NADES/PCW vehicle keep its soluble form
for longer durations in all these cultivation media in the
absence or the presence of tested cell types as compared with
DMSO. Therefore, the RES-NADES/PCW formulation,
similarly to RES-DMSO formulation, is compatible with in
vitro experiments to evaluate the RES capacity to inhibit
active MMP-9 produced by activated monocytes. Using a
range of decreasing RES concentrations prepared in both
formulations, we have observed that the NADES/PCW as
compared with DMSO, resulted in a considerable enhance-
ment by a factor of at least 10-fold of the RES capacity
to inhibit the MMP-9 activity. Thus, when using RES a
concentration as low as 1mM with the NADES/PCW
formulation, RES was able to reduce MMP-9 activity up to
52% as compared with RES formulated with DMSO, which
did not reduce this enzymatic activity at all, at this low
concentration. These ﬁndings contribute to a considerable
enhancement of the RES potential therapeutic effects in the
context of NADES formulation, since they support that
RES could exhibit its optimal effects under hormetic
conditions. While, a similar reduction rate of MMP-9
activity induced by RES formulated with DMSO was only
observed at concentrations of RES comprised between 10
and 20mM.
Due to the poor bioavailability of RES, Sinclair et al.
have suggested that a normal human weighing 75 kg would
need a daily RES dose close to 100mg/kg/day [40], which,
obviously, is not applicable. Consequently, new derivatives
and/or formulations of RES remain as unmet need that must
be overcome to reach both acceptable bioavailability and
activity of this compound.
This comparative study for the ﬁrst time the possibility of
getting improved drug’s responses at low concentrations, as
compared with traditional DMSO assays. We hypothesized
that with the NADES formulation, these interesting RES-
biological effects were probably due to the fact that NADES/
PCW could improve RES bioavailability, diffusion, trans-
port, and cell uptake for speciﬁc cell compartment localiza-
tion. In addition, taking into account the considerable
number of possible NADES combinations, potentially it
would be likely to optimize a particular NADES solvent for
RES and any other drug compound for their clinical use at
the lowest possible dosage. Since the limitation of the use of
Figure 3. In vitro cytotoxic effects of resveratrol formulated in NADES/PCW or DMSO. NADES/PCW or DMSO concentrated at 0.2% was
used to dissolve RES. In these Res solubilization conditions, increasing concentrations of 10, 20, 40, and 80mM RES were submitted to
MTT assay to assess their cytotoxic effects on either THP-1 monocytes (A) or primary HUVEC (B). Data were normalized against 0.2% of
DMSO or NADES/PCW alone as negative control and 1% SDS was used as positive control in cell culture medium. Values are mean of
three experiments standard deviation. p0.001.
Table 3. LC50 effect of NADES/PCW- or DMSO-formulated RES
on HUVEC and THP-1
LC50 (mM)
Cells NADES/PCW DMSO
HUVEC 60 65
THP-1 40 40
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DMSO in animal studies is due to its toxicity [41] and
although very encouraging results of our work, further
investigations (mainly pharmacokinetic properties) are
required to set up in vivo assays of RES administration with
non-covalent NADES formulations.
5 Conclusions
Altogether these results show, for the ﬁrst time, that
without altering the cell viability, the formulation of RES
dissolved in the particular NADES/PCW solution signiﬁ-
cantly enhances the RES inhibitory effects on MMP-9
activity of a more than 10-fold factor as compared with its
formulation in DMSO. These data evidenced that
NADES/PCW is able to enhance the hormetic mode of
action of RES to decrease the MMP-9 activity. In
addition, NADES are low-cost, simple to prepare, and
biodegradable resulting in less toxic “green” compounds.
Consequently, we propose that NADES could be use as
formulation method that would be considered as a suitable
“adjuvant” for druggable compounds, providing major
advantages, including bio-compatibility, lowered toxicity,
solubility, as well as the optimization of their active
concentrations for an enhanced biological activity.
Therefore, these ﬁndings could help to improve the
pharmacological activity of RES for preclinical and
clinical studies.
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